Skip to main content

Table 1 Characteristics of patients with psoriatic arthritis

From: Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: is there a link among fat and skin and joint involvement?

 N (%)Mean (SD)
Age (years) 53.12 (13.10)
Sex (Female)53 (54.6) 
Weight (kg)77.93 (15.98)
Height (cm)159.1 (20.2)
Body Mass Index (kg/m2)30.50 (5.73)
Waist circumference (cm)103.13 (13.26)
Female104.44 (13.40)
Male101.43 (13.49)
Time of Disease (years) 12.29 (14.42)
Skin19.27 (15.26)
Joint12.98 (14.43)
Skin activity
 PASI3.61 (6.84)
 BSA4.22 (9.31)
Joint activity
 Arthritis72 (74.2) 
 Enthesitis30 (30,9) 
 Dactylitis8 (8.72) 
 Axial34 (35,1) 
 DAS28-ESR3.54 (1.38)
  Remission21 (22.1)
  Low17 (17.9)
  Moderate/Severe57 (60.0)
 DAS28-CRP 3.05 (1.31)
  Remission34 (36.2)
  Low21 (22.3)
  Moderate/Severe39 (41.5)
 BASDAI3.15 (2.06)
   < 447 (52.8)
   ≥ 442 (47.2)
 HAQ0.92 (0.69)
 MDA22 (23.4) 
Psysical Activity (IPAQ)
 Inactive60 
 Minimally active27 
 Sufficiently active1 
 Active0 
 Very active0 
Drug therapy
  GCs11 (11.5) 
  NSAIDs4 (4.1) 
 Synthetic DMARDs monotherapy31 (31.9) 
 Synthetic DMARDs combination therapy10 (10.3) 
 TNF-blockers17 (17.5) 
  Infliximab4 (4.1) 
  Etanercept5 (5.2) 
  Adalimumab8 (8.2) 
 Synthetic and biological DMARDs14 (14.4) 
Comorbidities
 Diabetes, n (%)20 (20.6) 
 Hypertension, n (%)45 (46.4) 
 Dyslipidemia, n (%)43 (44.3) 
Concomitant Medications
 Insulin, n (%)7 (7.2) 
 Statins, n (%)33 (34.0) 
 Antidiabetic, n (%)20 (20.6) 
 Antihypertensive, n (%)46 (47.4) 
  1. Results shown as absolute values and respective percentage or mean and standard deviation (SD). GCs glucocorticoids, NSAIDs non-steroidal anti-inflammatory drugs, MTX methotrexate, LEF leflunomide, CsA cyclosporine A, TJN tender joint number, SJN swollen joint number, DMARDS Disease-modifying antirheumatic drugs, TNF Tumoral Necrosis Factor